Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
The primary study objective is to assess the safety of a monovalent vaccine of a new 6:2 reassortant in healthy adults prior to the release of the trivalent vaccine (FluMist). Safety will be demonstrated by similar fever rates (oral temperature ≥101°F) in vaccine and placebo recipients.
Age
18–64
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
18-64 years of age (not yet reached their 65th birthday);
In good health;
Available by telephone;
Ability to understand and comply with the requirements of the protocol; and
Signed informed consent.
You may not be if
Any condition, other than age, for which the inactivated influenza vaccine is indicated, including: chronic disorders of the pulmonary or cardiovascular systems, including asthma; chronic metabolic diseases (including diabetes mellitus) renal dysfunction, or hemoglobinopathies which required regular medical follow-up or hospitalization during the proceeding year;
Acute febrile (\>100.0°F oral) illness or clinically significant respiratory illness within the 14 days prior to enrollment;
Hypersensitivity to egg or egg protein;
Signs or symptoms of any immunosuppressive or immune deficiency disease, including HIV infection, or ongoing immunosuppressive therapy; or an immunosuppressed individual living in the same household;
Participation in another investigational trial within one month prior to enrollment or expected enrollment in another investigational trial during this study; and
Any condition that in the opinion of the investigator, might interfere with the vaccine evaluation.
Clareo Health | Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)
